Last updated on December 2019

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Brief description of study

The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of copanlisib in combination with nivolumab. The maximum tolerated dose will then be used in Phase 2 (dose expansion) of the study.

Clinical Study Identifier: NCT03735628

Find a site near you

Start Over

Sarcoma Oncology Center

Santa Monica, CA United States
  Connect »

Gabrail Cancer Center

Canton, OH United States
  Connect »

Rhode Island Hospital

Providence, RI United States
  Connect »